Niksan Pharmaceutical is worldâs leading manufacturer, trader, exporter and supplier of the Mometasone Furoate API and Mometasone Furoateformulations. NiksanPharmaceutical manufactures large quantity of Mometasone FuroateAPI and finishedproducts in Ankleshwar, Gujarat, India. Niksan Pharmaceutical and Niksan groupcompanies are the largest manufacturers and suppliers of Mometasone Furoate API and products.
Niksan pharmaceutical is also large exporter ofthe API and finished pharmaceutical products of Mometasone Furoate in many countries for years. The countries wherewe exporting are Puerto Rico, Nepal, Oman, United Arab Emirates, Qatar, UnitedStates, Hong Kong, Singapore, Philippines, Sri Lanka, Indonesia, New Zealand,United Kingdom, Saudi Arabia, Kenya, Canada, Malaysia, Iraq, Pakistan,Australia, Taiwan, Vietnam, Ireland, Thailand, Germany, France and many morecountries.
NiksanPharmaceutical provides API and finished formulations of Mometasone Furoatein all over Indian states Like Kerala, Gujarat,Haryana, Rajasthan, Madhya Pradesh, Uttar Pradesh, Rajasthan, Karnataka,Meghalaya, Tamilnadu, Goa, Sikkim, Assam, Punjab, Delhi, Bihar, Jammu KashmirEtc.
MometasoneFuroate is one type of medium strength corticosteroid. Mometasone Furoate use in the skin condition,fever and also use in treatment of asthma. Mometasone Furoate use to treat someskin conditions like psoriasis, rashes, and allergies.
CAS NO: 83919-23-7
MOLECULAR MASS: 427.36 g/mol
STORAGE CONDITIONS: Store in cool and dry place.Place medicine away from direct heat and sun light. Do not put medicine inbathroom or kitchen. Keep away from children and pets.
HOW TO USE: Mometasonecomes in the cream form for external use only, dot consume the medicine. Wash,clean and dry the part of skin before applying the cream. Do not use thecream on your face or in under arms or any open part of skin.
HOW MOMETASONE WORKS:Mometasone Furoate diffuses across cell membranes to activatepathways responsible for reducing inflammation. MometasoneFuroate also causes vasodilation of the smooth muscle and y this activityMometasone Furoate used in the treatment of asthma.
PHARMACOKINETICS OF MOMETASONE FUROATE: Mometasone Furoate rapidly absorbed in the body after topicalapplication. This drug takes 1-2.5 hours to reach the peak plasmaconcentration. The bio availability of Mometasone Furoate is <1%. Almost98%-99% of drug binds with the plasma proteins. Half-life of the MometasoneFuroate is approximately 5 hours. Almost 74% of drug eliminated unchanged byfaces and 8% of drug excreted by urination.
SIDE EFFECTS: The effectslike burning, irritation, itching and swelling may occur after application ofthis medicine. The other side effects like acne, swelling of skin,discolouration of skin, unwanted hairs and stretch marks are also seen in somepatients.
Take advice of your doctor if side effects likeweight loss, headache, vision problem, increase of urination seen in patients.
PRECAUTIONS: Tell yourdoctor if you are allergic to the Mometasone Furoate. Tell your doctor if youhave history like diabetes, weak immunity, poor blood circulation before takingmedication. If you are already using the other medication tell your doctorabout it. Take this medication in pregnancy or in lactation period when itâsstrictly needed.
CDSCO APPROVAL: Nadifloxacin (10mg/gm) +Mometasone Furoate (1mg/gm) cream approved by CDSCO in India in 17.08.2006,
Mometasone Furoate + Terbinafine HCl cream approved by CDSCO inIndia in 16.01.2002, Mometasone Furoate nasal spray 50 mcg/actuation(Additional Indication) approved by CDSCO in India in 21.05.2014,
Formoterol 6 mcg + Mometasone Furoate 100/200/400mcg Metered doseInhaler & Dry Powder Inhalation approved by CDSCO in India in 30.12.2009,
Tazarotene (1mg) + Mometasone Furoate (1mg) per gram cream approved by CDSCO inIndia in
Mometasone Furoate approved by CDSCO in India in 1990- October,
Mometasone Furoate aqueous nasal spray approved by CDSCO in Indiain 18.05.2001,
Tazarotene (0.05%) + Mometasone Furoate (0.1%) Cream(addl.strength) approved by CDSCO in India in 24.05.2005,
Nadifloxacin (1%) + Miconazole Nitrate (2%) + Mometasone Furoate(0.1%) Cream approved by CDSCO in India in 06.06.2006.
FORMULATIONSAVAILABLE IN MARKET:
Nadifloxacin (10mg/gm) + Mometasone Furoate (1mg/gm) cream
Mometasone Furoate + Terbinafine HCl cream
Mometasone Furoate nasal spray 50 mcg/actuation
Formoterol 6 mcg + Mometasone Furoate 100mcg Metered dose Inhaler
Formoterol 6 mcg + Mometasone Furoate 200mcg Metered dose Inhaler
Formoterol 6 mcg + Mometasone Furoate 400mcg Metered dose Inhaler
Tazarotene (1mg) + Mometasone Furoate (1mg) per gram cream
Mometasone Furoate aqueous nasal spray
Tazarotene (0.05%) + Mometasone Furoate (0.1%) Cream
Nadifloxacin (1%) + Miconazole Nitrate (2%) + Mometasone Furoate(0.1%) Cream
Note: Product protected by validpatents are not offered for sale in countries where such patents are stillvalid and its liability is at Buyers Risk